Some people with sickle cell disease have milder symptoms due to fetal hemoglobin persistence.

As previously reported, an intensely staining band of Type II hexokinase was observed in hemolysates from patients homozygous or heterozygous for the hereditary persistence of fetal hemoglobin on ...

FLT1 is among 14 new genetic markers of fetal hemoglobin the scientists identified from GWAS data gathered and used with permission from 3,751 people with sickle cell disease.

BEAM-101 aims to potentially alleviate the effects of mutations causing SCD by leading to increases in fetal hemoglobin (HbF), which inhibits hemoglobin S (HbS) polymerization.

--Beam Therapeutics Inc., a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/ 2 clinical ...

Updated data from 17 patients treated with BEAM-101 demonstrated robust and durable increases in fetal hemoglobin (HbF) and reductions in sickle hemoglobin (HbS), rapid neutrophil and platelet ...

It is known that increased production of alkali-resistant or fetal hemoglobin is usually associated with some genetically determined anemias such as thalassemia and sickle-cell anemia.

Treatment with BEAM-101 demonstrated robust and durable increases in fetal hemoglobin (HbF) and reductions in sickle hemoglobin (HbS), rapid neutrophil and platelet engraftment, and normalized or ...

About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.